Search
Corcept Therapeutics Inc
CORTAdd to Watchlist
79.910USD
-1.840-2.25%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
8.58BMarket Cap
174.48P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Corcept Therapeutics Inc is 7.67, ranking 96 out of 157 in the Pharmaceuticals industry. The average price target is 137.50, with a high of 144.90 and a low of 121.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
88.000
Target Price
+10.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Corcept Therapeutics Inc
CORT
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Corcept Therapeutics Inc's expected revenue for the next quarter?
Corcept Therapeutics Inc's expected revenue is 218.42M.
What is Corcept Therapeutics Inc's price target?
Analysts forecast that Corcept Therapeutics Inc's price target is USD 137.50, with the highest forecast at USD 144.90 and the lowest forecast at USD 121.00.
What is the analyst rating for Corcept Therapeutics Inc?
Based on the ratings of Corcept Therapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
